ARTHEx Biotech
Business Services · Spain · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Calle Eduardo Primo Yúfera 3, Paterna, V...Website
www.arthexbiotech.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About ARTHEx Biotech
ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed to precisely modulate gene expression. Its proprietary platform pairs selective oligonucleotides with tissue-specific delivery to reach skeletal muscle, heart, and brain. Its lead program, ATX-01, is in clinical evaluation for myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I/ IIa ArthemiR trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional areas of high unmet need across muscular, CNS, cardiac, and pulmonary diseases.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ARTHEx Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at ARTHEx Biotech
Click to see if ARTHEx Biotech had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
ARTHEx Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when ARTHEx Biotech launches new products
Check out if ARTHEx Biotech is spiking on competitors!
Earning: See what the market has to say on ARTHEx Biotech recently announced quarterly report
Check if ARTHEx Biotech has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once ARTHEx Biotech has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
ARTHEx Biotech is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ARTHEx Biotech is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ARTHEx Biotech.
ARTHEx Biotech financials insights
Gather financial insights about ARTHEx Biotech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Unspecified
$4.9M
2025
Series B
$87M
ARTHEx Biotech Tech Stack
A closer look at the technologies used by ARTHEx Biotech
Most Recent Scoops
Funding
Funding
Event
Events
Promotion
Executive Move
Funding
Executive Move
Board of Directors
ARTHEx Biotech News & Media
ARTHEx Biotech Publishes First Demonstration of Improvement in a DM1-related Behavioral Alteration in a Preclinical Model of Myotonic Dystrophy Type 1 (DM1)
New data show systemic delivery of antimiR-23b developed on ARTHEx BOOST-ON™ platform reaches the brain, corrects disease biology, and improves behavior—highlighting potential to address CNS manifestations of DM1 VALENCIA, Spain, July 23, 2026 /PRNewswire/ -- Arthex Biotech, a...ARTHEx Biotech Delivers Multiple Presentations at IDMC-15 Highlighting Clinical Progress of ATX-01 and Mechanistic Insights for Myotonic Dystrophy Type 1 (DM1) and 2 (DM2)
VALENCIA, Spain, May 27, 2026 /PRNewswire/ -- ARTHEx Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced multiple presentations at the 15th International Myotonic Dystrophy Consortium (IDMC-15) meeting, taking place...ARTHEx Biotech Announces Participation at the 25th Annual Needham Virtual Healthcare Conference
VALENCIA, Spain, April 14, 2026 /PRNewswire/ -- ARTHEx Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16, 2026....ARTHEx Biotech Granted FDA Fast Track Designation for ATX-01 for the Treatment of Myotonic Dystrophy Type 1 (DM1)
VALENCIA, Spain, March 11, 2026 /PRNewswire/ -- ARTHEx Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ATX-01 for the...
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding ARTHEx Biotech
Sign Up For FreeTo access detailed company insights
ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed to precisely modulate gene expression. Its proprietary platform pairs selective oligonucleotides with tissue-specific delivery to reach skeletal muscle, heart, and brain. Its lead program, ATX-01, is in clinical evaluation for myotonic dystrophy type 1 (DM1), a ra... Read More
